Rivaroxaban: An oral direct factor Xa inhibitor for the prevention of thromboembolism

Cardiology in Review

Volumn 17, Issue 4, 2009, Pages 192-197

  Chen, Terry ^a   Lam, Sum ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Antithrombotic; Factor Xa inhibitor; Prophylaxis; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; CARBAMAZEPINE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; JANTOVEN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN; XARELTO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTICOAGULANT THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; HYPOTENSION; INSOMNIA; LUNG EMBOLISM; NAUSEA; ORTHOPEDIC SURGERY; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, ORAL; ANTITHROMBIN III; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; MORPHOLINES; THIOPHENES; THROMBOEMBOLISM;

EID: 68049107440     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181aa2154     Document Type: Review

References (31)

1. Haines S, Zeolla M, Witt D. Venous thromboembolism. In: DiPiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. New York, NY: McGraw-Hill; 2005:1333-1364.
2. Geerts W, Bergqvist D, Pineo G, et al. Prevention of venous thromboembolism: the 8th ACCP evidence based clinical practice guidelines. Chest. 2008;133:381S-453S.
3. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.
4. Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag. 2007;3:321-329.
5. Xarelto: summary of product characteristic. Available at: http://www.xarelto. com/html/downloads/Xarelto-Summary-of-Product- Characteristics- 30Sept2008.pdf. Accessed March 5, 2009.
6. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48:5900-5908.
7. Gulseth M, Michaud J, Nutescu E. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65:1520-1529.
8. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, and oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
9. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor xa inhibitor. Semin Thromb Hemost. 2007;33:515-522.
10. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63:469-476.
11. Kubitza D, Becka M, Zuehlsdorf M, et al. Effects of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549-558.
12. Eriksson B, Borris L, Friedman R, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
13. Kakkar A, Brenner B, Eriksson B, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008;372:31-39.
14. Lassen M, Ageno W, Borris L, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358: 2776-2784.
15. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218-226.
16. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61: 873-880.
17. Weinz C, Schwarz D, Kubitza W, et al. Metabolism and excretion of rivaroxaban-an oral, direct factor Xa inhibitor-in rats, dogs and humans. Available at: http://dmd.aspetjournals.org/cgi/reprint/dmd.108.025569v1.pdf. Assessed March 15, 2009.
18. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939-an oral, direct factor xa inhibitor-in rats and dogs. Xenobiotica. 2005;35:891-910.
19. Weinz C, Schwartz T, Pleiss U, et al. Metabolism and distribution of (14C)BAY 59-7939-an oral, direct factor xa inhibitor-in rat, dog and human [abstract]. Drug Metab Rev. 2004;36(suppl 1):98.
20. About xarelto clinical studies. Available at: http://www.xarelto.com/ html/ press/pdf/About-Xarelto-Clinical-Studies.pdf. Accessed March 5, 2009.
21. Singer N. Panel votes to recommend anticlotting drug. New York Times. March 20, 2009.
22. Eriksson B, Borris L, Dahl O, et al. Oral, direct factor xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-128.
23. Eriksson B, Borris L, Dahl O, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.
24. Turpie A, Fisher W, Bauer K, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost. 2005; 3:2479-2486.
25. Turpie A, Bauer K, Davidson B, et al. Comparison of rivaroxaban-an oral, direct factor Xa inhibitor-and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase 3 study). Paper presented at: Annual Meeting of the European Federation of National Associations of Orthopaedics and Traumatology 2008; May 29-June 1, 2008; Nice, France. Abstract F85.
26. About RECORD studies. Available at: http://www.xarelto.com/html/press/ pdf/About-RECORD-studies.pdf. Accessed March 5, 2009.
27. Agnelli G, Gallus A, Goldhaber S, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-187.
28. Buller H, Lensing A, Prins M, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008;112:2242-2247.
29. Kubitza D, Becka M, Mueck W, et al. The effect of age and gender on the pharmacology and safety of the oral, direct factor Xa inhibitor [abstract]. J Thromb Haemost. 2007;5(suppl 2):628.
30. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218-226.
31. Press release. Available at: http://www.xarelto.com/scripts/pages/en/- press/ press-release.php?code=2008-0333E. Accessed March 5, 2009.